Hepatitis B virus X protein stabilizes cyclin D1 and increases cyclin D1 nuclear accumulation through ERK-mediated inactivation of GSK-3β

Cancer Prevention Research

Volumn 8, Issue 5, 2015, Pages 455-463

  Chen, Xiangmei ^a   Zhang, Ling ^b   Zheng, Sujun ^c   Zhang, Ting ^a   Li, Meng ^a   Zhang, Xiaolei ^a   Zeng, Zhenzhen ^a   McCrae, Malcolm A ^d   Zhao, Jingmin ^e   Zhuang, Hui ^a   Lu, Fengmin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Henan Cancer Hospital   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^e BEIJING 302 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; HEPATITIS B VIRUS X PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; CCND1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; 3T3 CELL LINE; ACTIVE TRANSPORT; ANIMAL; CELL CULTURE; CELL NUCLEUS; DISEASE COURSE; ENZYME ACTIVATION; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN STABILITY; PROTEIN TRANSPORT; VIROLOGY; VIRUS CELL TRANSFORMATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CYCLIN D1; DISEASE PROGRESSION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOGEN SYNTHASE KINASE 3; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; NIH 3T3 CELLS; PROTEIN STABILITY; PROTEIN TRANSPORT; TRANS-ACTIVATORS;

EID: 84942513073     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0384     Document Type: Article

References (33)

1. Michielsen P, Ho E. Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 2011;74:4-8.
2. Henkler FF, Koshy R. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepat 1996;3:109-21.
3. Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006;97:977-83.
4. Motavaf M, Safari S, Saffari JM, Alavian SM. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virol 2013;57:389-96.
5. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002;1:226-31.
6. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7:331-42.
7. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
8. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000;14:3102-14.
9. Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4- alphaB crystallin) complex. Mol Cell 2006;24:355-66.
10. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998;52:1-15.
11. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-62.
12. Ikeguchi M, Sakatani T, Ueta T, Kaibara N. Cyclin D1 expression and retinoblastoma gene protein (pRB) expression in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2001;127:531-6.
13. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34:207-18.
14. Joo M, Kang YK, Kim MR, Lee HK, Jang JJ. Cyclin D1 overexpression in hepatocellular carcinoma. Liver 2001;21:89-95.
15. Quelle DE, Ashmun RA, Shurtleff SA, Kato JY, Bar-Sagi D, Roussel MF, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-71.
16. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 2008;27:1231-42.
17. Park SG, Chung C, Kang H, Kim JY, Jung G. Upregulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J Biol Chem 2006;281:31770-7.
18. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of betacatenin. Mol Cell 2005;19:159-70.
19. Khattar E, Mukherji A, Kumar V. Akt augments the oncogenic potential of the HBx protein of hepatitis B virus by phosphorylation. FEBS J 2012;279:1220-30.
20. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997;11:957-72.
21. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003;63:7056-61.
22. Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, et al. Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer 2012;118:2431-42.
23. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006;25:998-1007.
24. Benzeno S, Diehl JA. C-terminal sequences direct cyclin D1-CRM1 binding. J Biol Chem 2004;279:56061-6.
25. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, Prat J, et al. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 2003;22:6115-8.
26. Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 2006;25:6291-303.
27. Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 2008;14:68-78.
28. Rimerman RA, Gellert-Randleman A, Diehl JA. Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation. J Biol Chem 2000;275:14736-42.
29. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009;156:885-98.
30. Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 2008;14:351-3.
31. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 2006;7:1377-88.
32. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
33. Aggarwal P, Lessie MD, Lin DI, Pontano L, Gladden AB, Nuskey B, et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev 2007;21:2908-22.